Regulatory Filings • Mar 15, 2018
Regulatory Filings
Open in ViewerOpens in native device viewer
Medistim REQUEST multicenter registry study results to be presented at AATS in April
(Oslo, March 15th, 2018) Medistim ASA (OSE: MEDI), a niche market leader within ultrasound technology with headquarter in Norway, that develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery, announces that the patient enrollment into the REQUEST registry study is completed and the final results have been accepted for presentation in the Late-Breaking Clinical Trial session at the AATS conference taking place in San Diego between April 28th and May 1st 2018.
The objective for the REQUEST study is to document how often the combination of high-resolution ultrasound imaging and transit time flow measurements (TTFM) performed with Medistim's VeriQC or MiraQ devices will change the surgical procedure. The surgical coronary artery bypass grafting (CABG) protocol includes ultrasound scanning of the aorta, conduit, target coronary vessel and anastomosis, as well as TTFM graft assessment.
More than 1000 CABG patients were included in this prospective multicenter registry study
between February 2015 and December 2017. Seven leading cardiac surgery centers from Europe, USA and Canada, led by Coordinating Investigator Professor David Taggart from the University of Oxford participated.
Preliminary results from 776 patients showed that 26% of the patient population had one or more surgical changes made to the procedure based on imaging and flow data. Now, the final results from more than 1000 patients have been accepted for presentation in the Late-Breaking Clinical Trial session at the 98th Annual Meeting for American Association for Thoracic Surgery (AATS) taking place in San Diego between April 28 - May 1, 2018.
«Medistim is very excited about reaching this important milestone", says Medistim President and CEO, Kari E. Krogstad. "For the first time, a large patient material is available documenting the number and type of surgical changes instigated by the combined use of Medistim TTFM and high-resolution ultrasound imaging. We believe that the REQUEST study results may provide new insights that could positively impact clinical outcomes and change clinical practice going forward."
About Medistim:
Medistim was established in 1984, and has a track record of profitable growth over the past >10 years. The company is a pioneer within its segment, and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the US, Germany, Denmark, UK, Spain and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa and South America. For more information, visit the Medistim home page:
www.Medistim.com
For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: [email protected]
CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: [email protected]
This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.